The companies will work under Bayer’s LifeHub UK, which forms part of the German healthcare company’s network of LifeHubs.
LifeHub UK has been launched to facilitate the development of AI-enabled imaging tools to speed-up and optimise disease diagnosis and data-driven discovery of drugs.
Sensyne Health is one of the first companies to move into the new LifeHub and will work with Bayer on AI-enabled radiology solutions using its clinical AI technology platform for automated image evaluation.
Under the project, the companies will examine three million anonymised patient records from the National Health Service (NHS) and imaging data provided via Sensyne Health’s alliances with NHS trusts.
The aim is to create digital solutions to assist radiologists in improving the diagnosis quality and efficiency for patients to receive appropriate treatment at the right time.
Bayer board member for innovation Kemal Malik said: “We firmly believe that artificial intelligence has transformative potential for healthcare, leading to enhancements in prediction, prevention and personalised treatments.”
Sensyne Health and Bayer are also planning for joint R&D activities in the future to develop AI-enabled imaging solutions.
Sensyne Health CEO Paul Drayson said: “Initiatives like this are essential to quickly maximise the opportunity AI presents to improve patient care and accelerate medical research.
“I’m delighted to be working with Bayer, extending our partnership to deliver the benefits of digital innovation directly to clinicians and patients.”
The companies previously collaborated to use clinical AI technology to speed-up the development of cardiovascular disease treatments.